FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172665612> ?p ?o ?g. }

• W3172665612 endingPage "3899" @default.
• W3172665612 startingPage "3892" @default.
• W3172665612 abstract "• 3-antigen hepatitis B vaccine (3A-HBV) has favorable immunogenicity and safety. • Both 3A-HBV production lots were statistically non-inferior to 1A-HBV. • Two 3A-HBV production lots (different facilities) were equivalent at day 210. • 3A-HBV (lot B) elicited a more rapid onset of seroprotection than 1A-HBV. • Lot B showed the same seroprotection rate after 2 doses as 1A-HBV after 3 doses. Sci-B-Vac®, a 3-antigen hepatitis B vaccine (3A-HBV), contains all three recombinant hepatitis B virus (HBV) envelope proteins (S, pre-S1, and pre-S2). In 2005, 3A-HBV manufacturing transferred facilities (A to B), where it continues to be manufactured. This phase 3, single-blind, randomized study, conducted at one site in Vietnam, compared efficacy and safety among two 3A-HBV lots, lot A and lot B, and a single-antigen hepatitis B vaccine (1A-HBV), Engerix-B®. Primary objective was to demonstrate equivalence at day 210 of two 3A-HBV lots in seroprotection rate (SPR; defined as percentage of participants achieving hepatitis B surface antigen antibody [anti-HBs] titers ≥ 10 mIU/mL). Secondary objectives were assessing immunogenicity at days 180, 210, and 360, and safety of 3A-HBV. 3A-HBV SPR equivalence was demonstrated at day 210 (lot A: 97.3% [95% CI: 92.4%, 99.4%] vs. lot B: 100.0% [97.0%, 100.0%]). Compared to 1A-HBV, lot B SPR was higher at day 180 (98.3% vs. 81.2%; difference: 17.1% [9.7%, 24.6%]) and non-inferior at day 210 (100% vs. 98.3%; difference: 1.7% [-0.6%, 4.1%]). 3A-HBV lot B showed the same SPR after 2 doses (98.3%) as 1A-HBV after 3 doses (98.3%). Adverse events (AEs) were comparable with both 3A-HBV lots (lot A: 68.7% vs. lot B: 54.2%), but higher than 1A-HBV (35.3%). Vaccination-related AEs included transient injection site pain (38.9%), myalgia (9.3%), and fatigue (7.5%). Eight serious AEs were reported (lot A: 3/134 [2.2%]; lot B: 1/134 [0.8%]; 1A-HBV: 4/133 [2.3%]). One serious AE, syncope, was noted as probably related to study vaccine, lot B. The two 3A-HBV lots had equivalent immunogenicity, but lot B elicited faster onset of seroprotection and higher anti-HBs titers than both lot A and 1A-HBV in an Asian population. This supports 3A-HBV lot B as an effective choice for HBV vaccination, with a favorable safety profile. ClinicalTrials.gov: NCT04531098." @default.
• W3172665612 created "2021-06-22" @default.
• W3172665612 creator A5016140316 @default.
• W3172665612 creator A5017186738 @default.
• W3172665612 creator A5090384530 @default.
• W3172665612 date "2021-06-01" @default.
• W3172665612 modified "2023-09-25" @default.
• W3172665612 title "Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial" @default.
• W3172665612 cites W1815984339 @default.
• W3172665612 cites W1835730169 @default.
• W3172665612 cites W1848545901 @default.
• W3172665612 cites W1964619581 @default.
• W3172665612 cites W1966448677 @default.
• W3172665612 cites W1971923366 @default.
• W3172665612 cites W1998949869 @default.
• W3172665612 cites W2000307707 @default.
• W3172665612 cites W2021707397 @default.
• W3172665612 cites W2062044670 @default.
• W3172665612 cites W2073754530 @default.
• W3172665612 cites W2078492033 @default.
• W3172665612 cites W2094575100 @default.
• W3172665612 cites W2109056360 @default.
• W3172665612 cites W2129628211 @default.
• W3172665612 cites W2135672952 @default.
• W3172665612 cites W2173781087 @default.
• W3172665612 cites W2462340700 @default.
• W3172665612 cites W2480418585 @default.
• W3172665612 cites W2888442525 @default.
• W3172665612 cites W2970571380 @default.
• W3172665612 cites W4244127058 @default.
• W3172665612 cites W794689245 @default.
• W3172665612 doi "https://doi.org/10.1016/j.vaccine.2021.05.067" @default.
• W3172665612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34116873" @default.
• W3172665612 hasPublicationYear "2021" @default.
• W3172665612 type Work @default.
• W3172665612 sameAs 3172665612 @default.
• W3172665612 citedByCount "6" @default.
• W3172665612 countsByYear W31726656122022 @default.
• W3172665612 countsByYear W31726656122023 @default.
• W3172665612 crossrefType "journal-article" @default.
• W3172665612 hasAuthorship W3172665612A5016140316 @default.
• W3172665612 hasAuthorship W3172665612A5017186738 @default.
• W3172665612 hasAuthorship W3172665612A5090384530 @default.
• W3172665612 hasBestOaLocation W31726656121 @default.
• W3172665612 hasConcept C147483822 @default.
• W3172665612 hasConcept C159047783 @default.
• W3172665612 hasConcept C203014093 @default.
• W3172665612 hasConcept C2522874641 @default.
• W3172665612 hasConcept C2777382497 @default.
• W3172665612 hasConcept C2777410769 @default.
• W3172665612 hasConcept C2780593183 @default.
• W3172665612 hasConcept C2780868878 @default.
• W3172665612 hasConcept C2781037505 @default.
• W3172665612 hasConcept C71924100 @default.
• W3172665612 hasConceptScore W3172665612C147483822 @default.
• W3172665612 hasConceptScore W3172665612C159047783 @default.
• W3172665612 hasConceptScore W3172665612C203014093 @default.
• W3172665612 hasConceptScore W3172665612C2522874641 @default.
• W3172665612 hasConceptScore W3172665612C2777382497 @default.
• W3172665612 hasConceptScore W3172665612C2777410769 @default.
• W3172665612 hasConceptScore W3172665612C2780593183 @default.
• W3172665612 hasConceptScore W3172665612C2780868878 @default.
• W3172665612 hasConceptScore W3172665612C2781037505 @default.
• W3172665612 hasConceptScore W3172665612C71924100 @default.
• W3172665612 hasIssue "29" @default.
• W3172665612 hasLocation W31726656121 @default.
• W3172665612 hasOpenAccess W3172665612 @default.
• W3172665612 hasPrimaryLocation W31726656121 @default.
• W3172665612 hasRelatedWork W1892905438 @default.
• W3172665612 hasRelatedWork W1998808386 @default.
• W3172665612 hasRelatedWork W2006079246 @default.
• W3172665612 hasRelatedWork W2028685116 @default.
• W3172665612 hasRelatedWork W2044794182 @default.
• W3172665612 hasRelatedWork W2078482420 @default.
• W3172665612 hasRelatedWork W2084781862 @default.
• W3172665612 hasRelatedWork W2439448351 @default.
• W3172665612 hasRelatedWork W4294579767 @default.
• W3172665612 hasRelatedWork W61381532 @default.
• W3172665612 hasVolume "39" @default.
• W3172665612 isParatext "false" @default.
• W3172665612 isRetracted "false" @default.
• W3172665612 magId "3172665612" @default.
• W3172665612 workType "article" @default.